OBJECTIVE: To develop a human immunodeficiency virus (HIV) staging system for sub-Saharan Africa on the basis of an evaluation of the World Health Organization (WHO) system and predictors of mortality. DESIGN: Prospective cohort study with 4 years of follow-up. SETTING: Kigali, Rwanda. PATIENTS: 412 HIV-infected women recruited from prenatal and pediatric clinics. MEASUREMENTS: Clinical signs and symptoms of HIV disease, laboratory assays (including complete blood count and erythrocyte sedimentation rate), and cumulative mortality. RESULTS: The WHO staging system includes a clinical and a laboratory axis. The clinical axis was revised by inclusion of oral candidiasis, chronic oral or genital ulcers, and pulmonary tuberculosis as "severe" disease (clinical stage IV); in addition, body mass index was substituted for weight loss in the definition for the wasting syndrome. The 36-month cumulative mortality was 7% for women in modified clinical stage I ("asymptomatic"), 15% for those in stage II, 19% for those in stage III, and 36% for those in stage IV (P < 0.001). The laboratory axis was revised by replacing lymphocyte count with hematocrit and erythrocyte sedimentation rate. The 36-month mortality was 10% for women in modified stage A ("normal" laboratory results) and 33% for those in stage B (erythrocyte sedimentation rate > 65 mm/h or hematocrit < 0.38) (P < 0.001). A single staging system combining clinical and laboratory criteria is proposed, with a 36-month mortality of 7% for women in combined stage I, 10% for those in stage II, 29% for those in stage III, and 62% for those in stage IV (P < 0.001). CONCLUSIONS: On the basis of this analysis, a staging system relevant for sub-Saharan Africa is proposed that reflects the range of HIV-related outcomes, has strong prognostic significance, includes inexpensive and available laboratory tests, and can be used by both clinicians and researchers.
OBJECTIVE: To develop a human immunodeficiency virus (HIV) staging system for sub-Saharan Africa on the basis of an evaluation of the World Health Organization (WHO) system and predictors of mortality. DESIGN: Prospective cohort study with 4 years of follow-up. SETTING: Kigali, Rwanda. PATIENTS: 412 HIV-infectedwomen recruited from prenatal and pediatric clinics. MEASUREMENTS: Clinical signs and symptoms of HIV disease, laboratory assays (including complete blood count and erythrocyte sedimentation rate), and cumulative mortality. RESULTS: The WHO staging system includes a clinical and a laboratory axis. The clinical axis was revised by inclusion of oral candidiasis, chronic oral or genital ulcers, and pulmonary tuberculosis as "severe" disease (clinical stage IV); in addition, body mass index was substituted for weight loss in the definition for the wasting syndrome. The 36-month cumulative mortality was 7% for women in modified clinical stage I ("asymptomatic"), 15% for those in stage II, 19% for those in stage III, and 36% for those in stage IV (P < 0.001). The laboratory axis was revised by replacing lymphocyte count with hematocrit and erythrocyte sedimentation rate. The 36-month mortality was 10% for women in modified stage A ("normal" laboratory results) and 33% for those in stage B (erythrocyte sedimentation rate > 65 mm/h or hematocrit < 0.38) (P < 0.001). A single staging system combining clinical and laboratory criteria is proposed, with a 36-month mortality of 7% for women in combined stage I, 10% for those in stage II, 29% for those in stage III, and 62% for those in stage IV (P < 0.001). CONCLUSIONS: On the basis of this analysis, a staging system relevant for sub-Saharan Africa is proposed that reflects the range of HIV-related outcomes, has strong prognostic significance, includes inexpensive and available laboratory tests, and can be used by both clinicians and researchers.
Entities:
Keywords:
Africa; Africa South Of The Sahara; Cohort Analysis; Demographic Factors; Developing Countries; Diseases; Eastern Africa; Examinations And Diagnoses; French Speaking Africa; Hiv Infections; Hiv Serodiagnosis; International Agencies; Laboratory Examinations And Diagnoses; Methodological Studies; Mortality; Organizations; Physical Examinations And Diagnoses; Population; Population Dynamics; Prospective Studies; Research Report; Rwanda; Signs And Symptoms; Studies; Un; Viral Diseases; Who
Authors: S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi Journal: AIDS Res Hum Retroviruses Date: 2001-07-01 Impact factor: 2.205
Authors: Patrick S Sullivan; Ulgen Fideli; Kristin M Wall; Elwyn Chomba; Cheswa Vwalika; William Kilembe; Amanda Tichacek; Nicole Luisi; Joseph Mulenga; Eric Hunter; Debrah Boeras; Susan Allen Journal: AIDS Date: 2012-01-14 Impact factor: 4.177
Authors: Kayvon Modjarrad; Isaac Zulu; David T Redden; Lungowe Njobvu; David O Freedman; Sten H Vermund Journal: Am J Trop Med Hyg Date: 2005-10 Impact factor: 2.345
Authors: Kristin M Wall; Bellington Vwalika; Lisa Haddad; Naw H Khu; Cheswa Vwalika; William Kilembe; Elwyn Chomba; Rob Stephenson; David Kleinbaum; Azhar Nizam; Ilene Brill; Amanda Tichacek; Susan Allen Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Philip J Peters; Isaac Zulu; Nzali G Kancheya; Shabir Lakhi; Elwyn Chomba; Cheswa Vwalika; Dhong-Jin Kim; Ilene Brill; Jareen Meinzen-Derr; Amanda Tichacek; Susan A Allen Journal: AIDS Res Hum Retroviruses Date: 2008-07 Impact factor: 2.205
Authors: Melody E Roelke; Meredith A Brown; Jennifer L Troyer; Hanlie Winterbach; Christiaan Winterbach; Graham Hemson; Dahlem Smith; Randall C Johnson; Jill Pecon-Slattery; Alfred L Roca; Kathleen A Alexander; Lin Klein; Paolo Martelli; Karthiyani Krishnasamy; Stephen J O'Brien Journal: Virology Date: 2009-05-22 Impact factor: 3.616